AI's Rapid Expansion and Evolving Landscape in Healthcare

Key Intelligence

• ■AI continues to attract substantial investment, with new deals and funding rounds supporting drug discovery and health tech startups like Intero Biosystems (Disrupt 2026 winner) and Nvidia-backed Iambic ($150M IPO).
• ■Major pharmaceutical companies, such as AstraZeneca, are forming significant collaborations with AI biotech firms like insitro, with deals totaling up to $1.86 billion, to accelerate the discovery of novel therapeutics for complex diseases.
• ■AI-powered solutions are demonstrating real-world traction in patient care, with telemedicine providers like Rocket Doctor AI reporting strong Q3 2026 growth and new AI models improving diagnostics for issues like lung sounds and uncovering unseen health issues in CT scans.
• ■The rapid pace of AI development is raising critical questions about clinical trial frameworks, medical data infrastructure, and the need for new regulatory guidelines to ensure responsible and effective integration into medical practice.